Could an MS pill protect the brain in Alzheimer's? new trial launches

NCT ID NCT06639282

Recruiting now Disease control Sponsor: St. Joseph's Hospital and Medical Center, Phoenix Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase II trial tests whether siponimod, a drug already approved for multiple sclerosis, can safely slow brain atrophy in people with mild Alzheimer's disease. Over 18 months, 105 participants will receive either the drug or a placebo. Researchers will measure brain volume changes, cognitive function, and biomarkers to see if the drug offers any benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: siponimod (Mayzent)
What this could lead to: If successful, this could point toward a new treatment that slows brain shrinkage and cognitive decline in early Alzheimer's disease.
What could go wrong: This is an early Phase II trial with only 105 participants, so results may not be conclusive. Siponimod also has known risks like infections and heart issues, and it is unclear if benefits seen in MS will translate to Alzheimer's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE COGNITIVE IMPAIRMENT, MILD MCI WITH INCREASED RISK FOR ALZHEIMER DISEASE MILD ALZHEIMER DISEASE

Contacts and locations

Locations

St. Joseph's Hospital and Medical Center
RECRUITING

Phoenix, Arizona, 85013, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.